FOY-305-03:FOY-305 TQT study(COVID-19)

JRCT ID: jRCT2071200109

Registered date:08/03/2021

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: COVID-19
• Date of first enrollment: 06/04/2021
• Target sample size: 39
• Study type: Interventional
• Intervention(s): Single administration of FOY-305, pracebo and moxifloxacin

Outcome(s)

• Primary Outcome: Prolongation of QT/QTc interval

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: <= 45age old
• Gender: Male
• Include criteria: Japanese healthy adult male, >=18 and <=45 of age, >=18.5 and <25.0 of BMI
• Exclude criteria: Medical history of severe disease, severe allergy for foods and drugs, QTcF>=450ms at SCR

Related Information

• Primary Sponsor: Osawa Masahiro